Dr Agnieszka Michael

Senior Lecturer

Qualifications: MD PhD

Email:
Phone: Work: 01483 68 8546
Room no: 04 PGM 03

Office hours

9am-5pm Mon-Fri

Further information

Biography

Qualifications

 

PhD October 2006

                                              

MRCP UK July 1998 London

                                              

PLAB October 1995 London

                                            

MBBS June 1993 Medical School Wroclaw Poland

 

Previous Positions

 

05 SEPT’ 06- 09 DEC’07            Guy’s and St Thomas’ NHS FT, Specialist Registrar rotation

05 MAR’ 06- 04 SEPT’ 06           St George’s Hospital, Haemato-Oncology, Specialist Registrar

05 SEPT’ 05- 04 MARCH’ 06        Guy’s and St.Thomas’ NHS FT, Specialist Registrar                                             

01 JUL’ 05 - 04 SEPT’ 05             St George’s Hospital London, Specialist Registrar                                             

01 MAY’ 01 – 30 OCT’ 04           Clinical research fellow , PhD project, 

01 JUNE’ 99-30 APRIL’ 01        St. George’s Hospital, Specialist Registrar rotation                                                 

01 APR’ 99-30 MAY’ 99            Royal Marsden Hospital, Breast Unit, Specialist Registrar

                                   

SHO posts:

AUG’ 98-FEB’ 99                       Royal Marsden Hospital, Sutton,

FEB’ 96-AUG’ 98                      Two-year medical rotation in Havering Hospitals in Essex.

Research Interests

Biomarkers for Cancer 

Ovarian Cancer

Publications

Journal articles

  • Annels NE, Simpson GR, Denyer M, McGrath SE, Falgari G, Killick E, Eeles R, Stebbing J, Pchejetski D, Cutress R, Murray N, Michael A, Pandha H. (2014) 'Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.'. Clin Exp Immunol,
  • Morgan R, Boxall A, Harrington KJ, Simpson GR, Michael A, Pandha HS. (2014) 'Targeting HOX transcription factors in prostate cancer.'. BMC Urol, England: 14
  • McGrath SE, Michael A, Morgan R, Pandha H. (2013) 'EN2: a novel prostate cancer biomarker.'. Biomark Med, England: 7 (6), pp. 893-901.
  • McGrath SE, Michael A, Pandha H, Morgan R. (2013) 'Engrailed homeobox transcription factors as potential markers and targets in cancer'. FEBS Letters, 587 (6), pp. 549-554.
  • McGrath SE, Michael A, Pandha H, Morgan R. (2013) 'Engrailed homeobox transcription factors as potential markers and targets in cancer.'. FEBS Lett, Netherlands: 587 (6), pp. 549-554.
  • Michael A, Relph K, Annels N, Pandha H. (2013) 'Prostate cancer vaccines.'. Expert Rev Vaccines, England: 12 (3), pp. 253-262.

    Abstract

    In 2010, the US FDA approved the first therapeutic cancer vaccine for the treatment of castration refractory prostate cancer - sipuleucel-T. Prostate cancer is an ideal model for cancer vaccine development based on the ready demonstration of humoral and cellular immunity to a range of cancer antigens as well as often slow progression which means that patients who are otherwise well may have a radiologically evaluable minor progression, after conventional treatment and can undergo vaccine therapy over sufficient periods of time, so as to allow the generation of a robust antitumor response. The association of prostate cancer with one of the few serum cancer biomarkers in general use has also allowed assessment of response and risk stratification of patients. In this review, we will examine key aspects of the evolution of prostate cancer vaccines, which provides an accurate prototype for other cancers, and the challenges we face.

  • Larbi E, Madhuri K, Essapen S, Butler-Manuel S, Tailor A, Michael A. (2013) 'The Effect of Age on First-line Chemotherapy for Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma'. Clinical Oncology, 25 (1), pp. 75-75.
  • Larbi E, Madhuri K, Essapen S, Butler-Manuel S, Tailor A, Michael A. (2012) 'The Effect of Age on First-line Chemotherapy for Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma'. Clinical Oncology,
  • Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS. (2012) 'Targeting the HOX/PBX dimer in breast cancer.'. Springer Breast Cancer Res Treat, Netherlands: 136 (2), pp. 389-398.
  • Morgan R, Boxall A, Simpson GR, Michael A, Pandha HS, Harrington KJ, Gillett C. (2012) 'Targeting the HOX/PBX dimer in breast cancer'. Breast Cancer Research and Treatment, 136 (2), pp. 389-398.
  • McGrath S, Madhuri TK, Susarla S, Haagsma B, Saleh F, Michael A. (2012) 'Low grade serous ovarian carcinoma with metastases to the sternum and ribs.'. Pathology, England: 44 (5), pp. 481-482.
  • Chen SS, Michael A, Butler-Manuel SA. (2012) 'Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.'. Discov Med, United States: 13 (68), pp. 7-17.
  • Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H, Annels N, Michael A, Pandha H. (2011) 'Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer.'. Clin Cancer Res, United States: 17 (5), pp. 1090-1098.

    Abstract

    Prostate cancer (PC) is the second most common cause of cancer related death in men. A number of key limitations with prostate specific antigen (PSA), currently the standard detection test, has justified evaluation of new biomarkers. We have assessed the diagnostic potential of Engrailed-2 (EN2) protein, a homeodomain-containing transcription factor expressed in PC cell lines and secreted into the urine by PC in men.

  • Morgan RM, Ismail M, Boxall A, Bhaat A, Hindley R, Michael A, Langley SM, Zylstra J, Pandha HS. (2011) 'ENGRAILED-2 (EN2): A HIGHLY SPECIFIC URINARY BIOMARKER FOR THE EARLY DIAGNOSIS OF PROSTATE CANCER'. ELSEVIER SCIENCE BV EUR UROL SUPPL, 10 (2), pp. 64-64.
  • Gray S, Pandha HS, Michael A, Middleton G, Morgan R. (2011) 'HOX genes in pancreatic development and cancer.'. JOP, Italy: 12 (3), pp. 216-219.
  • Kelly ZL, Michael A, Butler-Manuel S, Pandha HS, Morgan RG. (2011) 'HOX genes in ovarian cancer'. Springer Journal of Ovarian Research, 4 (1)

    Abstract

    The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity during development. Here we review a number of recent studies showing that HOX genes are strongly expressed in ovarian cancer, and that in some cases the expression of specific HOX genes is sufficient to confer a particular identity and phenotype upon cancer cells. We also review the recent advances in elucidating the different functions of HOX genes in ovarian cancer. A literature search was performed using the search terms HOX genes (including specific HOX genes), ovarian cancer and oncogenesis. Articles were accessed through searches performed in ISI Web of Knowledge, PubMed and ScienceDirect. Taken together, these studies have shown that HOX genes play a role in the oncogenesis of ovarian cancer and function in the inhibition of apoptosis, DNA repair and enhanced cell motility. The function of HOX genes in ovarian cancer oncogenesis supports their potential role as prognostic and diagnostic markers, and as therapeutic targets in this disease.

  • Lunt C, Barber N, Montgomery A, Kalsi V, Parker T, Michael A, Pandha H, Hindley R. (2010) 'CYTOREDUCTIVE NEPHRECTOMY IN THE TYROKINASE INHIBITOR ERA'. MARY ANN LIEBERT INC J ENDOUROL, 24, pp. A303-A303.
  • Michael A, Relph K, Pandha H. (2010) 'Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents.'. Wiley-Blackwell International Journal of Cancer, United States: 127 (6), pp. 1251-1258.

    Abstract

    Anti-angiogenic agents targeting tumour vasculature have an established place in clinical practice, and new data are constantly emerging. However, despite rapid clinical uptake, a very large number of questions regarding these agents remain unanswered. One of the main hurdles in clinical practice is lack of accurate and feasible ways of assessing response to drug beyond tumour reduction on conventional imaging. This review summarises recent developments in the field of biomarkers of response to anti-VEGF drugs.

  • Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. (2010) 'Targeting HOX and PBX transcription factors in ovarian cancer'. BIOMED CENTRAL LTD BMC CANCER, 10 Article number ARTN 89
  • Michael A, John J, Meyer B, Pandha H. (2010) 'Activation and Genetic Modification of Human Monocyte-Derived Dendritic Cells using Attenuated Salmonella typhimurium'. THESCIENTIFICWORLD LTD THESCIENTIFICWORLDJOURNAL, 10, pp. 393-401.
  • Michael A, Syrigos K, Pandha H. (2009) 'Prostate cancer chemotherapy in the era of targeted therapy'. NATURE PUBLISHING GROUP PROSTATE CANCER AND PROSTATIC DISEASES, 12 (1), pp. 13-16.
  • Michael A, Politi E, Havranek E, Corbishley C, Karapanagiotou L, Anderson C, Relph K, Syrigos KN, Pandha H. (2007) 'Prognostic significance of erythropoietin expression in human renal cell carcinoma.'. BJU Int, England: 100 (2), pp. 291-294.
  • Michael A, Hedayati B, Dalgleish AG. (2007) 'Disease regression in malignant melanoma: Spontaneous resolution or a result of treatment with antioxidants, green tea, and pineapple cores? A case report'. SAGE PUBLICATIONS INC INTEGR CANCER THER, 6 (1), pp. 77-79.
  • Michael A, Hill M, Maraveyas A, Dalgleish A, Lofts F. (2007) '13-cis-Retinoic Acid in Combination with Gemcitabine in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer - Report of a Pilot Phase II Study'. W B Saunders Clinical Oncology, 19 (2), pp. 150-153.
  • Hu JCC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC. (2006) 'A phase I study of OncoVEX(GM-CSF), a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 12 (22), pp. 6737-6747.
  • Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. (2005) 'Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables'. Clin Cancer Res, 11 (12), pp. 4469-4478.
  • Michael A, Maravcyas A, Hill M, Wasan H, Lofts F. (2001) 'Preliminary results of phase I/II study to investigate the use of gemcitabine in combination with ralitrexed in locally advanced or metastatic adenocarcinoma of the pancreas'. CHURCHILL LIVINGSTONE BRITISH JOURNAL OF CANCER, 85, pp. 55-55.

Conference papers

  • Kelly Z, Pandha H, Morgan R, Michael A. (2012) 'HXR9 AND PARP INHIBITION -A NOVEL THERAPEUTIC IN OVARIAN CANCER'. OXFORD UNIV PRESS ANNALS OF ONCOLOGY, Vienna, AUSTRIA: 37th Congress of the European-Society-for-Medical-Oncology (ESMO) 23, pp. 325-325.
  • Kelly Z, Pandha H, Madhuri K, Morgan R, Michael A. (2012) 'HOX GENE EXPRESSION IN OVARIAN CANCER'. OXFORD UNIV PRESS ANNALS OF ONCOLOGY, Vienna, AUSTRIA: 37th Congress of the European-Society-for-Medical-Oncology (ESMO) 23, pp. 68-68.
  • McGrath S, Annels NE, Madhuri TK, Haagsma B, Larbi ED, Pandha HS, Michael A. (2012) 'Engrailed protein: A cancer-specific marker in epithelial ovarian cancer'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 30 (15)
  • Coward JIG, Larbi ED, Pandha H, Michael A. (2011) 'The effect of age on first-line sunitinib treatment in patients with renal cell carcinoma (RCC).'. J Clin Oncol 29: 2011 (suppl; abstr e15096), Chicago USA: ASCO
  • Gungor H, Saleem A, Agarwal R, Blagden S, Michael A, Stronach EA, Chen M, Pickford E, Rama NR, Lewis YL, Carme SC, Salinas C, Smith DA, Krachey E, Santiago-Walker A, Gunn RN, El-Bahrawy M, Babar, SA, Morris R, Gabra H. (2011) 'Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.'. J Clin Oncol 29: 2011 (suppl; abstr 5064), Chicago USA: ASCO
  • Michael A, Riley, C, Bokaee S, Denyer M, Pandha H, Annels N. (2011) 'EN2: A candidate antigen for the development of targeted therapies in ovarian cancer.'. JCO, Chicago: ASCO (J Clin Oncol 29: 2011 (suppl; abstr e15528))
  • Michael A, Zylstra J, Pandha H. (2011) 'The sun study-a biobank of sequential blood samples from patients with prostate cancer'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 50-50.
  • Larbi E, Madhuri TK, Essapen S, Michael A. (2010) 'The impact of age on first-line chemotherapy treatment of epithelial ovarian cancer and primary peritoneal carcinoma'. Chicago USA: ASCO (J Clin Oncol 28:15s, 2010 (suppl; abstr 5118))
  • Michael A, Plowright L, Boxall A, Bhatt A, Di Palma S, Parker C, Pandha H. (2010) 'Evaluation of EN2 as a urine-based biomarker for prostate cancer.'. J Clin Oncol 28, 2010 (suppl; abstr e15129), Chicago USA: ASCO

Page Owner: am0035
Page Created: Tuesday 3 January 2012 15:11:18 by pr0004
Last Modified: Monday 16 January 2012 14:58:21 by gs0006
Expiry Date: Saturday 27 November 2010 15:58:24
Assembly date: Tue Apr 15 22:22:00 BST 2014
Content ID: 70703
Revision: 2
Community: 1196